VRTX Dips 17% In One Month: Does It Lead the Pack?
Here is how Vertex Pharmaceuticals (VRTX) stacks up against its peers in size, valuation, growth and margin.
- VRTX’s operating margin of -1.7% is negative, lower than most peers – trailing REGN (27.0%).
- VRTX’s revenue growth of 10.5% in the last 12 months is strong, outpacing IONS, BIIB, REGN but lagging ACAD, BMRN.
- VRTX’s stock is down 19.0% in last 1 year, and trades at a PE of 27.5; it underperformed ACAD, IONS.
As a quick background, Vertex Pharmaceuticals provides therapies for cystic fibrosis, marketing SYMDEKO, ORKAMBI, and KALYDECO, with a pipeline including VX-864 for AAT deficiency in Phase 2 trials.
| VRTX | ACAD | IONS | BIIB | BMRN | REGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 99.9 | 4.5 | 6.8 | 19.9 | 11.3 | 61.7 |
| Revenue ($ Bil) | 11.4 | 1.0 | 0.7 | 9.8 | 3.1 | 14.2 |
| PE Ratio | 27.5 | 20.1 | -14.8 | 13.5 | 17.1 | 13.8 |
| LTM Revenue Growth | 10.5% | 14.4% | -7.6% | 1.6% | 18.4% | 5.4% |
| LTM Operating Margin | -1.7% | 8.9% | -65.9% | 23.2% | 25.3% | 27.0% |
| LTM FCF Margin | 30.6% | 8.7% | -78.5% | 23.4% | 22.6% | 25.0% |
| 12M Market Return | -19.0% | 68.7% | -11.6% | -32.9% | -35.2% | -50.9% |
Why does this matter? VRTX just went down -16.9% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell VRTX Stock to see if Vertex Pharmaceuticals is really a falling knife. Sharp dips often come with rebound opportunities – see how the stock has dipped and recovered in the past through VRTX Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| VRTX | 10.5% | 11.7% | 10.5% | 17.9% |
| ACAD | 14.4% | 31.8% | 40.4% | 6.8% |
| IONS | -7.6% | -10.5% | 34.1% | -27.5% |
| BIIB | 1.6% | -1.6% | -3.3% | -7.4% |
| BMRN | 18.4% | 18.0% | 15.4% | 13.5% |
| REGN | 5.4% | 8.3% | 7.8% | -24.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| VRTX | -1.7% | -2.1% | 38.3% | 47.6% |
| ACAD | 8.9% | 8.8% | -10.1% | -43.2% |
| IONS | -65.9% | -67.4% | -44.9% | -69.8% |
| BIIB | 23.2% | 22.9% | 18.6% | 28.5% |
| BMRN | 25.3% | 16.6% | 7.7% | 2.7% |
| REGN | 27.0% | 28.1% | 30.9% | 38.9% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| VRTX | 27.5 | -193.9 | 29.0 | 22.3 |
| ACAD | 20.1 | 13.4 | -83.7 | -11.9 |
| IONS | -14.8 | -11.5 | -19.8 | -19.9 |
| BIIB | 13.5 | 13.6 | 32.2 | 13.2 |
| BMRN | 17.1 | 29.3 | 108.0 | 135.4 |
| REGN | 13.8 | 17.4 | 23.7 | 17.8 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.